Delving into the Latest Updates on Propiverine Hydrochloride with Synapse

A total of 40 volunteers women with a diagnosis of interstitial cystitis. Their ages ranged from 25 to 40 years old; their body mass index was > 30 kg/m2 and were randomly assigned to a group (A) received interferential current at the lower abdomen, and also received traditional medicine or group (B) received traditional medicine for 8 successive weeks. Both of the groups received the treatment program for 8 successive weeks. Assessment of pain perception and disability level for all patients in both groups (A&B) were done through Visual analogue scale, O'Leary-Sant Symptom Index or Interstitial Cystitis Index (ICSI) and blood cortisol concentration were done before and after the treatment program.

Start Date01 Jan 2019

Sponsor / Collaborator

Cairo University

NCT03602508

/ CompletedNot Applicable

Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania

The purpose of this study is to descriptively evaluate the persistence among adults treated with mirabegron or antimuscarinics in Australia, South Korea and Taiwan.
This study will also assess the persistence to the overall Overactive bladder (OAB) treatments of a patient, regardless of treatment discontinuation or switch to other OAB medications.

Start Date20 Jul 2018

Sponsor / Collaborator

Astellas Pharma Singapore Pte Ltd.

NCT02294396

/ CompletedPhase 4

Postmarketing Study of Mirabegron in Japan: Long-term Add-on Therapy With Antimuscarinics in Patients With Overactive Bladder Treated With Mirabegron

The objective of the study was to evaluate the safety and efficacy of add-on therapy with anticholinergics in patients with OAB on mirabegron.

Start Date28 Oct 2014

Sponsor / Collaborator

Astellas Pharma, Inc.

100 Clinical Results associated with Propiverine Hydrochloride

Login to view more data

100 Translational Medicine associated with Propiverine Hydrochloride

Login to view more data

100 Patents (Medical) associated with Propiverine Hydrochloride

Login to view more data

1,859

Literatures (Medical) associated with Propiverine Hydrochloride

01 Nov 2024·BMJ Medicine

Risk of dementia associated with anticholinergic drugs for overactive bladder in adults aged ≥55 years: nested case-control study

Article

Author: Avery, Anthony J ; Iyen, Barbara ; Bell, Brian Gregory ; Ashcroft, Darren M ; Bishara, Delia ; Orrell, Martin William ; Coupland, Carol ; Dening, Tom

ObjectiveTo investigate whether different anticholinergic drug treatments for overactive bladder have differential risks for incident dementia, in a large representative population of older adults in England.DesignNested case-control study.SettingGeneral practices in England providing data to the Clinical Practice Research Datalink (CPRD) GOLD database, with linked patient admission records from secondary care (Hospital Episode Statistics), 1 January 2006 and 16 February 2022Participants170 742 patients aged ≥55 years, with a first reported diagnosis of dementia during the study period, matched by age, sex, and general practice with 804 385 individuals without dementia (controls).InterventionsCumulative drug use (defined using total standardised daily dose) of different anticholinergic drugs used for the treatment of an overactive bladder, and a non-anticholinergic drug, mirabegron, in the period 3-16 years before a diagnosis of dementia (or equivalent date in matched controls).Main outcome measuresOdds ratios for onset of dementia associated with the different anticholinergic drugs used for the treatment of an overactive bladder, adjusted for sociodemographic characteristics, clinical comorbidities, and use of other anticholinergic drug treatments.ResultsThe study population comprised 62.6% women, and median age was 83 (interquartile range 77-87) years. 15 418 (9.0%) patients with dementia and 63 369 (7.9%) controls without dementia had used anticholinergic drugs for the treatment of an overactive bladder in the 3-16 years before diagnosis (or equivalent date for controls). The adjusted odds ratio for dementia associated with the use of any anticholinergic drug used to treat an overactive bladder was 1.18 (95% confidence interval (CI) 1.16 to 1.20), and was higher in men (1.22, 1.18 to 1.26) than women (1.16, 1.13 to 1.19). The risk of dementia was substantially increased with the use of oxybutynin hydrochloride (adjusted odds ratio 1.31, 95% CI 1.21 to 1.42 and 1.28, 1.15 to 1.43 for use of 366-1095 and >1095 total standardised daily doses, respectively), solifenacin succinate (1.18, 1.09 to 1.27 and 1.29, 1.19 to 1.39), and tolterodine tartrate (1.27, 1.19 to 1.37 and 1.25, 1.17 to 1.34). No significant increases in the risk of dementia associated with darifenacin, fesoterodine fumarate, flavoxate hydrochloride, propiverine hydrochloride, and trospium chloride were found. The association between mirabegron, a non-anticholinergic drug, and dementia was variable across the dose categories and might be caused by previous use of anticholinergic drugs for the treatment of an overactive bladder in these individuals.ConclusionsOf the different anticholinergic drugs used to treat an overactive bladder, oxybutynin hydrochloride, solifenacin succinate, and tolterodine tartrate were found to be most strongly associated with the risk of dementia in older adults. This finding emphasises the need for clinicians to take into account the possible long term risks and consequences of the available treatment options for an overactive bladder in older adults, and to consider prescribing alternative treatments that might be associated with a lower risk of dementia.

01 Aug 2024·Journal of Dairy Science

Effect of 200 μg of gonadorelin hydrochloride at the first GnRH of a CO-Synch program on ovulation rate and pregnancies per artificial insemination in Holstein heifers

Article

Author: Menezes, M C G ; Melo, D B ; Castro, T ; Lima, F S ; Salman, S ; Cotterman, R F ; Coelho, W M ; Monteiro, H F ; Marques, T C ; Conley, A J ; Macedo, I M

The initial ovulatory response during synchronization programs is often low in dairy heifers, largely due to follicular dynamics and hormonal dynamics. Specifically, the progesterone (P4) concentration at the time of the first GnRH treatment in a breeding program can influence the LH response, often resulting in a suboptimal ovulatory response. The objective of this study was to determine the effect of the highest label dose 200 μg (100 μg vs. 200 μg) of GnRH (50 μg of gonadorelin hydrochloride per mL; Factrel, Zoetis Inc. Madison, NJ) at the first GnRH of a 6-d CO-Synch plus P4 device program on ovulatory response and pregnancy per AI (P/AI) in first service in Holstein heifers. A total of 1,308 Holstein heifers were randomly allocated at the beginning of a 6-d CO-Synch program at day 0 to receive either i.m. treatment of 100 μg (2CC, n = 655) or 200 μg (4CC, n = 653) of GnRH. Also, at d 0, heifers received an intravaginal insert with 1.38 g of P4 (Eazi-Breed CIDR Cattle Insert, Zoetis Inc.). On day 6, the insert was removed, and i.m. treatment of 25 mg of PGF_2α (12.5 mg of dinoprost tromethamine/mL; Lutalyse HighCon Injection, Zoetis Inc.) was administered. On d 7, a second i.m. treatment of 25 mg of PGF_2α was given, followed on d 9 by concurrent i.m. treatment of 100 μg of GnRH, and timed AI. A subset of 396 heifers had their ovaries scanned to evaluate ovulatory response, and blood samples were collected to measure the serum concentration of P4 at d 0 and d 6 of the study. The P4 concentrations at d 0 were categorized as low (≤3 ng/mL) or high (>3 ng/mL). The ovulatory response was greater for heifers receiving 4CC than 2CC at d 0 (54.7% vs. 42.8%). The ovulatory response was greater for low P4 than high P4 at d 0 (54.3% vs. 37.8%). However, we did not observe an interaction between treatment and P4 concentrations (low P4 2CC = 48.6% vs. high P4 2CC = 30.0%; low P4 4CC = 60.0% vs. high P4 4CC = 45.5%). The receiver operating characteristic curve analysis indicated that P4 concentrations at d 0 treatment could predict the ovulatory response, although the area under the curve was only 0.6. As expected, heifers that ovulated had increased P/AI (no = 55.6% vs. yes = 67.7%); however, we found no effect of treatment on P/AI (2CC = 63.3% vs. 4CC = 59.6%), and no interactions between treatment and ovulation and treatment and P4 (high vs. low) for pregnancy outcomes. In summary, P4 concentration and increasing the dose of GnRH at d 0 positively affected ovulatory response in Holstein heifers. However, there was no interaction between treatment and P4 on ovulation and no subsequent impact of GnRH dose on P/AI.

01 Aug 2024·Reproductive BioMedicine Online

Article

RESEARCH QUESTIONHow is the production of progesterone (P₄) and 17-hydroxy-P₄ (17-OH-P₄) regulated between theca cells and granulosa cells during the follicular phase, during ovulation and after transformation into a corpus luteum?DESIGNThree cohorts were examined: (i) 31 women undergoing natural and stimulated cycles, with serum hormone measurements taken every 3 days; (ii) 50 women undergoing ovarian stimulation, with hormone concentrations in serum and follicular fluid assessed at five time points during final follicle maturation; and (iii) 12 women undergoing fertility preservation, with hormone concentrations evaluated via the follicular fluid of small antral follicles.RESULTSIn the early follicular phase, theca cells primarily synthesized 17-OH-P₄ while granulosa cells produced limited P₄, maintaining the P₄:17-OH-P₄ ratio <1. As follicles reached follicle selection at a diameter of approximately 10 mm, P₄ synthesis in granulosa cells was up-regulated, but P₄ was mainly accumulated in follicular fluid. During final maturation, enhanced activity of the enzyme HSD3B2 in granulosa cells enhanced P₄ production, with the P₄:17-OH-P₄ ratio increasing to >1. The concentration of 17-OH-P₄ in the luteal phase was similar to that in the follicular phase, but P₄ production increased in the luteal phase, yielding a P₄:17-OH-P₄ ratio significantly >1.CONCLUSIONSThe P₄:17-OH-P₄ ratio reflects the activity of granulosa cells and theca cells during the follicular phase and following luteinization in the corpus luteum. Managing the function of granulosa cells is key for reducing the concentration of P₄ during ovarian stimulation, but the concerted action of FSH and LH on granulosa cells during the second half of the follicular phase makes this complex.

100 Deals associated with Propiverine Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01007	Propiverine Hydrochloride	G04BD06	DB12278

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Neurogenic detrusor overactivity	CA	Duchesnay, Inc.	05 Jan 2017
Urinary Bladder, Overactive	CA	Duchesnay, Inc.	05 Jan 2017
Urinary Incontinence	JP	Taiho Pharmaceutical Co., Ltd.	02 Apr 1993

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Urinary Incontinence, Urge	Phase 2	CN	APOGEPHA Arzneimittel GmbH	01 Jan 2010
Urinary Bladder, Neurogenic	Phase 2	RO	APOGEPHA Arzneimittel GmbH	01 Dec 2004
Urinary Bladder, Neurogenic	Phase 2	DE	APOGEPHA Arzneimittel GmbH	01 Dec 2004
Urinary Bladder, Neurogenic	Phase 2	AT	APOGEPHA Arzneimittel GmbH	01 Dec 2004
syndrome; salt-losing, adrenogenital syndrome	Phase 2	-	APOGEPHA Arzneimittel GmbH	01 Oct 2004
Neurogenic detrusor overactivity	Phase 2	-	APOGEPHA Arzneimittel GmbH	01 Jun 2004
Urinary Bladder, Overactive	Phase 2	-	APOGEPHA Arzneimittel GmbH	01 Jun 2004
Urinary Incontinence	Phase 2	-	APOGEPHA Arzneimittel GmbH	01 Jun 2004

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02294396 (CTgov)	Phase 4	Urinary Bladder, Overactive	649	Mirabegron tablet+Solifenacin tablet (Mirabegron + Solifenacin)	ppuellbpub(ovqiopolcz) = rjfexqkxwg jiizmodcct (xgbmctwdgd, hxvissvota - ionbzzxuco) View more	-	24 Dec 2018
				Mirabegron tablet+Propiverine tablet (Mirabegron + Propiverine)	ppuellbpub(ovqiopolcz) = lwpbuxuiui jiizmodcct (xgbmctwdgd, riibdyhvdq - fzcejdfjmw) View more
NCT01512004 (Pubmed \| BJU Int) Manual	Phase 3	Urinary Bladder, Overactive	324	propiverine	gqvtaclfzk(wzdcznemdz) = begtrwtmhv gpaxyckczt (zlqndiunid, 4.1) View more	Non-inferior	01 Jan 2017
				tolterodine	gqvtaclfzk(wzdcznemdz) = kqetlecbco gpaxyckczt (zlqndiunid, 5.1) View more
NCT00903045 (Pubmed \| BJU Int)	Phase 4	Urinary Bladder, Overactive	264	Propiverine 20 mg	pxpwitrjsu(zxwrgrxkau) = jbkbvkzpoy yfkxldqkho (eprtjpscwp )	Positive	01 Jun 2010
				Placebo	pxpwitrjsu(zxwrgrxkau) = trppajcgme yfkxldqkho (eprtjpscwp )
NCT00795925 (Pubmed \| Clin Pharmacokinet)	Phase 2	Urinary Bladder, Overactive	25	Propiverine 5 mg	ektheexkwu(nfjcdouwjj) = Most of the adverse events that were probably or possibly drug related were reported for patients in the high-dose group (>0.45 mg/kg) kavakhsgba (uyckmamrsj )	-	01 May 2010
				Propiverine 10 mg
NCT00603343 (Pubmed \| Eur Urol)	Phase 3	Urinary Incontinence \| Urinary Bladder, Overactive	171	Propiverine	qsuoxfzqah(jewkjkebcj) = hbprddqnml lhvlnxgkts (uxmlxtuztt ) View more	Positive	01 Mar 2009
				Placebo	qsuoxfzqah(jewkjkebcj) = jsnttdoelb lhvlnxgkts (uxmlxtuztt ) View more